Glaukos (NYSE:GKOS) Given New $110.00 Price Target at Citigroup

Glaukos (NYSE:GKOS) had its price objective trimmed by Citigroup from $140.00 to $110.00 in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

Several other brokerages have also weighed in on GKOS. William Blair raised Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. UBS Group increased their target price on Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Mizuho set a $130.00 target price on Glaukos in a research report on Thursday, July 31st. Truist Financial dropped their target price on Glaukos from $126.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Finally, The Goldman Sachs Group began coverage on Glaukos in a research report on Wednesday, October 1st. They issued a “buy” rating and a $103.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.00.

Glaukos Stock Performance

GKOS stock opened at $84.24 on Tuesday. Glaukos has a 12-month low of $77.10 and a 12-month high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $88.14 and its 200 day simple moving average is $93.11. The firm has a market cap of $4.83 billion, a P/E ratio of -51.05 and a beta of 0.76.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The firm had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. During the same period last year, the company earned ($0.52) earnings per share. The firm’s revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Glaukos will post -1.08 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GKOS. Norges Bank bought a new position in Glaukos during the second quarter valued at about $76,314,000. Primecap Management Co. CA boosted its stake in Glaukos by 50.0% during the second quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock valued at $188,814,000 after buying an additional 609,523 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Glaukos by 56.5% during the first quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier’s stock valued at $125,735,000 after buying an additional 461,386 shares in the last quarter. AustralianSuper Pty Ltd bought a new position in Glaukos during the second quarter valued at about $41,946,000. Finally, William Blair Investment Management LLC boosted its stake in Glaukos by 52.4% during the second quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock valued at $117,347,000 after buying an additional 390,805 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.